2-(4-imidazolyl)-cyclopropylamine | 24160-41-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(4-imidazolyl)-cyclopropylamine
• 英文别名: 3(S)-(1H-imidazol-4-yl)-2-(R)-cyclopropylamine；2(S)-(1H-4-imidazolyl)-3(S)-cyclopropylamine；2-(1(3)H-imidazol-4-yl)-cyclopropylamine；2-(4-Imidazolyl) cyclopropylamine；2-(1H-imidazol-5-yl)cyclopropan-1-amine
• CAS: 24160-41-6
• 化学式: C₆H₉N₃
• mdl: MFCD18450018
• 分子量: 123.158
• InChiKey: OWWNABDDYQLERE-UHFFFAOYSA-N

物化性质

• 沸点：
  359.0±35.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
  申请人：——

  公开号：US20010047100A1

  公开（公告）日：2001-11-29

  Novel intermediates useful in the preparation of optically active H 3 histamine receptor antagonist 2-(4-imidazoyl)-cyclopropyl derivatives are disclosed.

  披露了在制备具有光学活性的H3组胺受体拮抗剂2-(4-咪唑基)-环丙基衍生物中有用的新型中间体。
• Novel alicyclic imidazoles as H3 agents
  申请人：——

  公开号：US20020042400A1

  公开（公告）日：2002-04-11

  Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H 3 receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.

  本文介绍了脂环咪唑化合物、含有这些化合物的药用组合物以及在控制或预防涉及组胺H3受体的疾病状态（如过敏、炎症、低血压、青光眼、睡眠障碍、胃肠道高低动力状态、心血管疾病、中枢神经系统低高活性、阿尔茨海默病、精神分裂症、肥胖症和偏头痛等）的制剂中使用此类化合物的方法。
• Novel alicylic imidazoles as H3 agents
  申请人：——

  公开号：US20040029943A1

  公开（公告）日：2004-02-12

  Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H 3 receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.

  本发明涉及脂环型咪唑化合物；含有这种化合物的药物活性组合物；以及在制剂中使用这种化合物来控制或预防组织胺H3受体参与的疾病状态，例如过敏、炎症、低血压、青光眼、睡眠障碍、胃肠道过度和过度活动状态、心血管疾病、中枢神经系统的低活性和高活性、阿尔茨海默病、精神分裂症、肥胖症和偏头痛。
• Composition pharmaceutique contenant des dérivés de l'histamine
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP0214058B1

  公开（公告）日：1992-05-06
• COMPOSES AGONISTES DU RECEPTEUR H3 DE L'HISTAMINE A USAGE THERAPEUTIQUE, COMPOSITIONS PHARMACEUTIQUES AGISSANT COMME AGONISTES DUDIT RECEPTEUR ET PROCEDE DE PREPARATION
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP0482183B1

  公开（公告）日：1997-07-30